<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st May 2013//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_130501.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23539106</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0391-1977</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>38</Volume>
                    <Issue>1 Suppl 1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Minerva endocrinologica</Title>
                <ISOAbbreviation>Minerva Endocrinol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Guidelines for the diagnosis, prevention and treatment of osteoporosis. Italian Osteoporosis, Mineral Metabolism, and Skeletal Diseases Society].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-30</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <CollectiveName>Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro</CollectiveName>
                </Author>
            </AuthorList>
            <Language>ita</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Practice Guideline</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Linee Guida per la Diagnosi, Prevenzione e Terapia dell'Osteoporosi.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Minerva Endocrinol</MedlineTA>
            <NlmUniqueID>8406505</NlmUniqueID>
            <ISSNLinking>0391-1977</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Bone Density Conservation Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Selective Estrogen Receptor Modulators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance>Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4EQZ6YO2HI</RegistryNumber>
                <NameOfSubstance>denosumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7440-70-2</RegistryNumber>
                <NameOfSubstance>Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Absorptiometry, Photon</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bone Density</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fractures, Spontaneous</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hormone Replacement Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hyperparathyroidism</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Osteoporosis</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Osteoporosis, Postmenopausal</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Selective Estrogen Receptor Modulators</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Vertebroplasty</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Vitamin D</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">R07130000</ArticleId>
            <ArticleId IdType="pubmed">23539106</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436674</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sigmoid colon torsion: mortality and relevant risk factors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>127-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">1080</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sigmoid volvulus is an important acute intestinal obstruction, leading to high mortality and requiring urgent operation. The purpose of this study is to analyze risk factors for mortality in patients that were operated on due to sigmoid volvulus at our Department.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The retrospective study included 158 patients, who were operated on due to sigmoid volvulus between January 1994-December 2010, in terms of age, gender, complaints at admission, physical signs, period of symptoms before admission, associated diseases, laboratory and radiological parameters, hospital stay, morbidity, and mortality.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study consisted of 135 men (85.4%) and 23 women (14.6%), with a mean age of 62.54 years. Cardiovascular disease and respiratory disease were present in 34 (21.5%) and 42 (26.6%) patients, respectively. Urgent operation was undertaken in 125, while 33 received elective surgery. Abdominal distension and pain was evident in all the patients. Generalized tenderness was detected in 58.2%, while 70.9% had hyperactive bowel sound with tympanism. Plain radiograph revealed an impression of &quot;omega ans&quot; in all patients, while free air was detected in 11.4% of them. Risk factors for mortality included age (p = 0.008), delayed admission (p = 0.001), cardiovascular and respiratory diseases (p = 0.001), fluid-electrolyte imbalance (p =0.001), presence of necrosis (p = 0.001), and major contamination (p = 0.001). Wound infection and intraabdominal abscess were more common in patients that developed mortality (p = 0.001 and p = 0.002).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Complications like wound infection and intraabdominal abscess are more frequent in the patients with the risk of mortality. Delayed admission results in higher risk of mortality. Mortality rates can be reduced by early admission, preoperative intensive resuscitation, suitable antibiotics, and emergent and viable surgery.  </AbstractText>
            </Abstract>
            <Affiliation>Department of General Surgery, Dicle University, Diyarbakir, Turkey. draonder@gmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Onder</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kapan</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arikanoglu</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palanci</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gumus</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aliosmanoglu</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aldemir</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Abdominal Abscess</DescriptorName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Abdominal Pain</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Emergencies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intestinal Volvulus</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Length of Stay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sigmoid Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Surgical Procedures, Elective</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Surgical Wound Infection</DescriptorName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time-to-Treatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436674</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436673</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Current practice and recent advances in pediatric pain management.</ArticleTitle>
            <Pagination>
                <MedlinePgn>112-26</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3095</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Differently from the adult patients, in pediatric age it is more difficult to assess and treat efficaciously the pain and often this symptom is undertreated or not treated. In children, selection of appropriate pain assessment tools should consider age, cognitive level and the presence of eventual disability, type of pain and the situation in which it is occurring. Improved understanding of developmental neurobiology and paediatric analgesic drugs pharmacokinetics should facilitate a better management of childhood pain.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The objective of this review is to discuss current practice and recent advances in pediatric pain management.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Using PubMed we conducted an extensive literature review on pediatric pain assessment and commonly used analgesic agents from January 2000 to January 2012.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A multimodal analgesic regimen provides better pain control and functional outcome in children. Cooperation and communication between the anaesthesiologist, surgeon, and paediatrician are essential for successful anaesthesia and pain management.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pediatrics, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. achiaretti@yahoo.it</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chiaretti</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pierri</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valentini</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Russo</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gargiullo</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riccardi</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Analgesics</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Analgesics</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interdisciplinary Communication</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pain Management</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">standards</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pain Measurement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pain Threshold</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Patient Care Team</DescriptorName>
                <QualifierName MajorTopicYN="N">standards</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pediatrics</DescriptorName>
                <QualifierName MajorTopicYN="Y">standards</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436673</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436669</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>65-85</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3085</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this Part II psychiatric disorders coexisting with organic diseases are discussed. &quot;Comorbidity phenomenon&quot; defines the not univocal interrelation between medical illnesses and psychiatric disorders, each other negatively influencing morbidity and mortality. Most severe psychiatric disorders, such as schizophrenia, bipolar disorder and depression, show increased prevalence of cardiovascular disease, related to poverty, use of psychotropic medication, and higher rate of preventable risk factors such as smoking, addiction, poor diet and lack of exercise. Moreover, psychiatric and organic disorders can develop together in different conditions of toxic substance and prescription drug use or abuse, especially in the emergency setting population. Different combinations with mutual interaction of psychiatric disorders and substance use disorders are defined by the so called &quot;dual diagnosis&quot;. The hypotheses that attempt to explain the psychiatric disorders and substance abuse relationship are examined: (1) common risk factors; (2) psychiatric disorders precipitated by substance use; (3) psychiatric disorders precipitating substance use (self-medication hypothesis); and (4) synergistic interaction. Diagnostic and therapeutic difficulty concerning the problem of dual diagnosis, and legal implications, are also discussed. Substance induced psychiatric and organic symptoms can occur both in the intoxication and withdrawal state. Since ancient history, humans selected indigene psychotropic plants for recreational, medicinal, doping or spiritual purpose. After the isolation of active principles or their chemical synthesis, higher blood concentrations reached predispose to substance use, abuse and dependence. Abuse substances have specific molecular targets and very different acute mechanisms of action, mainly involving dopaminergic and serotoninergic systems, but finally converging on the brain's reward pathways, increasing dopamine in nucleus accumbens. The most common substances producing an addiction status may be assembled in depressants (alcohol, benzodiazepines, opiates), stimulants (cocaine, amphetamines, nicotine, caffeine, modafinil), hallucinogens (mescaline, LSD, ecstasy) and other substances (cannabis, dissociatives, inhalants). Anxiety disorders can occur in intoxication by stimulants, as well as in withdrawal syndrome, both by stimulants and sedatives. Substance induced mood disorders and psychotic symptoms are as much frequent conditions in ED, and the recognition of associated organic symptoms may allow to achieve diagnosis. Finally, psychiatric and organic symptoms may be caused by prescription and doping medications, either as a direct effect or after withdrawal. Adverse drug reactions can be divided in type A, dose dependent and predictable, including psychotropic drugs and hormones; and type B, dose independent and unpredictable, usually including non psychotropic drugs, more commonly included being cardiovascular, antibiotics, anti-inflammatory and antineoplastic medications.</AbstractText>
            </Abstract>
            <Affiliation>Department of Emergency Medicine, A. Gemelli Hospital, Catholic University of the Sacred Heart, Rome, Italy. americotesta@gmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Testa</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giannuzzi</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sollazzo</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petrongolo</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernardini</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dain</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Comorbidity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Emergencies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Emergency Service, Hospital</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Emergency Services, Psychiatric</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mental Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Substance-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436669</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436666</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review.</ArticleTitle>
            <Pagination>
                <MedlinePgn>45-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3078</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metformin is known to be rarely associated with lactic acidosis, a serious condition with a poor prognosis.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review the National Pharmacovigilance Network of the Italian Medicines Agency reporting cases of metformin-associated lactic acidosis.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The National Pharmacovigilance Network of the Italian Medicines Agency, was searched for cases of lactic acidosis that occurred in a 10 years period (from November 2001 to October 2011). Data were analyzed, to identify associated clinical features. A systematic literature research was performed to identify other large case series on metformin associated lactic acidosis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Metformin was the antidiabetic drug most frequently associated with lactic acidosis in the assessed period. Metformin-associated lactic acidosis was the most frequent serious adverse reaction related to metformin reported to the national authority (18.2% of all 650 adverse drug reactions reported). There were 59 cases of metformin-associated lactic acidosis (mortality rate of 25.4%). In most patients (89.8%) there was at least one risk factor for the occurrence of lactic acidosis. The predictors of death were low arterial blood pH and absence of acute renal failure. The systematic research of the literature identified only six case-series with more than 30 patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the second largest case series ever reported on metformin-associated lactic acidosis. We confirmed that this rare complication of metformin is frequently fatal. Death can be predicted when the patient arrive in the hospital with low pH and, not intuitively, if the patient has no acute kidney injury. Risk minimisation measures taken at national level to prevent this serious complication are described.</AbstractText>
            </Abstract>
            <Affiliation>Italian Medicines Agency, Rome, Italy.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Renda</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mura</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finco</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrazin</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pani</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landoni</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>657-24-9</RegistryNumber>
                <NameOfSubstance>Metformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acidosis, Lactic</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Health Surveys</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Hospitalization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436666</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436664</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>34-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3074</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Arsenic trioxide (As2O3) is an environmental toxicant as well as an effective anti cancer agent against many types of cancers. It is a promising drug for patients with relapsed acute promyelocytic leukaemia (APL), but its clinical efficacy is burdened by the serious cardiac toxicities.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The present study was designed to investigate the toxic mechanism of arsenic in cardiac tissue at its clinically relevant concentrations.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Experimental rats were administered with As2O3 2, 4 and 8 mg/kg body weight, orally for a period of 45 days. Cardiac toxicities were recorded by lipid peroxidation, activities of glutathione dependent antioxidant and antiperoxidative enzymes, cardiac arsenic accumulation and histopathological changes.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In vivo studies revealed a significant rise in lipid peroxidation, decline in reduced glutathione, glutathione dependent antioxidant enzymes and antiperoxidative enzymes in the cardiac tissue of arsenic treated rats. The extent of free radical production was found increased with periodic rise in the arsenic concentration. The experimental group which received 8 mg/kg body weight of arsenic exhibited the highest deposition of arsenic in cardiac tissue. Light microscopic examination of cardiac tissues in arsenic treated rats has showed increased structural abnormalities like myocardial fibre swelling, capillary congestion and micro-haemorrhages.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study concludes that the mechanism of arsenic induced cardiac toxicity is associated with the accumulation of arsenic in tissue and the extent of free radical production.</AbstractText>
            </Abstract>
            <Affiliation>School of Biosciences, Mahatma Gandhi University, Kottayam, Kerala, India. harinairsbs@gmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mathews</LastName>
                    <ForeName>V V</ForeName>
                    <Initials>VV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paul</LastName>
                    <ForeName>M V S</ForeName>
                    <Initials>MV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abhilash</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manju</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abhilash</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nair</LastName>
                    <ForeName>R H</ForeName>
                    <Initials>RH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Arsenicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Oxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1327-53-3</RegistryNumber>
                <NameOfSubstance>arsenic trioxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>70-18-8</RegistryNumber>
                <NameOfSubstance>Glutathione</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.6</RegistryNumber>
                <NameOfSubstance>Catalase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.9</RegistryNumber>
                <NameOfSubstance>Glutathione Peroxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance>Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.8.1.7</RegistryNumber>
                <NameOfSubstance>Glutathione Reductase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance>Glutathione Transferase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arsenicals</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Body Burden</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Catalase</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Reductase</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Heart Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukemia, Promyelocytic, Acute</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oxides</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436664</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436661</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>13-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">1382</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The contrast-induced nephropathy (CIN) is the third most common cause of acute renal failure (ARF) and the worsening in a pre-existing chronic renal failure (CRF), with a foreseeable increase of morbidity, mortality, length of the stay in hospital and, as a consequence, of the health costs. We studied the effectiveness of N-acetylcysteine (NAC) associated with sodium bicarbonate (Na2HCO3) infusion in order to prevent CIN in patients undergoing coronary angiography with administration of contrast medium.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">296 patients with indication to perform coronary angiography were included in a randomized, observational study. All patients were randomly assigned to receive pre- and post-contrast hydration with 1500 ml of 0.9% saline solution infusion (Group A) or NAC (1200 mg × 2 days) + Na2HCO3 (Group B). The primary end-point was to examine CIN appearance, defined as a raise in serum values of Cr (Creatinine) ≥ 0.5 mg/dl or ≥ 25% within 24-72 hours after the exposure to the contrast medium.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">It has been observed a frequency of CIN of 9.4% in Gr. A compared to 7.2% in Gr. B. Nevertheless, when we put these results through a more accurate screening according to gender, degree of raise in creatinine levels and the extent of change in GFR (glomerular filtration rate), we observed a very different behaviour. In patients with normal Cr and CrCl (Clearance of Creatinine) the frequency of CIN was similar in both group A and B (approximately 5%). In patients with normal Cr but reduced ClCr the use of NAC was more effective than hydration in preventing CIN (0% vs 18% in prevalence respectively in B and A group). In patients with moderately reduced Cr and CrCl, hydration with saline solution was more effective than NAC + Na2HCO3 (8.6% vs 17.6%) while in patients with severe CRF the combined use of NAC + Na2HCO3 showed off to be very successful in preventing CIN compared to the merely hydration (0% vs 50%).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients affected by severe CRF who are undergoing investigations with contrast medium administration, such as coronary angiography, the combined use of NAC + Na2HCO3 infusion significantly reduces the risk of developing CIN. In other circumstances the final result is related to the degree of previous GFR or creatinine values alteration or to gender. In such situations the combined use of both substances is more questionable and sometimes ineffective.</AbstractText>
            </Abstract>
            <Affiliation>Department of Cardiology, Sapienza University, Rome, Italy. Alessandrinicola@libero.it</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alessandri</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lanzi</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garante</LastName>
                    <ForeName>C M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tersigni</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sergiacomi</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petrassi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Matteo</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tufano</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Contrast Media</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>144-55-8</RegistryNumber>
                <NameOfSubstance>Sodium Bicarbonate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>60-27-5</RegistryNumber>
                <NameOfSubstance>Creatinine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>616-91-1</RegistryNumber>
                <NameOfSubstance>Acetylcysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7647-14-5</RegistryNumber>
                <NameOfSubstance>Sodium Chloride</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acetylcysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Cardiology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Contrast Media</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Coronary Angiography</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Creatinine</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Fluid Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium Bicarbonate</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium Chloride</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436661</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436660</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An evaluation of cases of pneumonia that occurred secondary to hydrocarbon exposure in children.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-12</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3064</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Hydrocarbon pneumonia is distinct among the types of childhood pneumonia in that it has a different pathogenesis and treatment and is preventable. In this study, the cases of 54 children with hydrocarbon pneumonia admitted to the Dicle University Medical Faculty Pediatric Chest Diseases Unit between the years 2006 and 2010 were analyzed retrospectively.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The medical records of 54 patients diagnosed with pneumonia after ingesting/inhaling hydrocarbons were analyzed retrospectively. Age, sex, presenting symptoms, clinical status, radiological and laboratory findings and response to treatment and prognosis were noted.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">35 (64.8%) of the patients were male, 19 (35.2%) were female and the ages of the patients ranged from 1 to 5 with an average of 2.49 ± 0.80. The etiologies of the pneumonia were thinner (33%), naphta (3.7%) and kerosene. In 49 of the patients (90.7%), the symptoms started to occur the day the patient was exposed to hydrocarbons. The average length of hospital stay was 4.0 ± 2.3 days. Six patients were treated in the intensive care unit (ICU), and one patient with hydrocarbon pneumonia due to kerosene ingestion died. Inhaled corticosteroids were administered to 18 patients who were progressively deteriorating and inhaled salbutamol was given to 16 patients with bronchospasm. Patients with radiological findings on their chest X-rays and auscultatory findings were found to have longer hospital stays (p &lt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To prevent chemical pneumonia, precautions must be taken to stop children under 5 years of age from using/abusing chemical substances. Although some cases of chemical pneumonia lead to death, with diligent care and treatment, the outcomes are promising. The patients in this study group responded well to treatment with inhaled corticosteroids and salbutamol.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pediatric Pulmonology, Dicle University School of Medicine, Diyarbakir, Turkey. drvelatsen@hotmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sen</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelekci</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Selimoglu Sen</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yolbas</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Günes</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abakay</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuat Gurkan</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hydrocarbons</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoconstriction</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hydrocarbons</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intensive Care Units</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Length of Stay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pneumonia</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436660</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23436659</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1128-3602</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of isolation rooms on the prevalence of hospital acquired pneumonia in a respiratory ICU.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">3061</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The incidence of hospital acquired pneumonia (HAP) varies according to the type of intensive care units (ICUs).</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aims of this study were to determine the frequency of hospital acquired pneumonia (HAP) and the effect of isolation rooms on the frequency of pneumonia in the ICU.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The present investigation was carried out between January 2004 and July 2008. The ICU, which was 4-bed ward-type between January 2004 and February 2006 (1st period), was reconfigured as isolated rooms with only 2 beds each after March 2006 (2nd period). 153 and 379 patients were followed up in the ICU in the 1st and 2nd periods, respectively. Blood, sputum, and deep tracheal aspiration cultures were used for the isolation of the causative agents.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant difference was detected between the general characteristics of patients. HAP developed in 101 patients (19%). The prevalence of HAP was 22.9% in the 1st period and 17.4% in the 2nd period. During the 1st and 2nd periods, the HAP infection densities were 22.2 and 16.1/1000 patient-days and the ventilator-associated pneumonia densities were 48.1 and 37.6/1000 ventilator-days, respectively. Eighty-six percent of HAP was ventilator-associated pneumonia (VAP).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Isolation rooms in the ICU may be an effective strategy to control and decrease the rate of pneumonia in the ICU in addition to other preventive strategies.</AbstractText>
            </Abstract>
            <Affiliation>Department of Chest Diseases, University of Osmangazi, Eskisehir, Turkey. iucgun@ogu.edu.tr</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ucgun</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dagli</LastName>
                    <ForeName>C E</ForeName>
                    <Initials>CE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiremitci</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yildirim</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ak</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aslan</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">APACHE</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cross Infection</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="N">transmission</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hospital Mortality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infection Control</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Intensive Care Units</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Patient Isolation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pneumonia, Bacterial</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="N">transmission</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pneumonia, Ventilator-Associated</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiration, Artificial</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23436659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23187688</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>30</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1543-0790</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>10 Suppl 18</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical advances in hematology &amp; oncology : H&amp;O</Title>
                <ISOAbbreviation>Clin Adv Hematol Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-16</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Treatments for non-small cell lung cancer (NSCLC) are based on the broad categories of squamous or non-squamous histology. Frontline treatment options include pemetrexed and cisplatin, pemetrexed and a taxane, gemcitabine with cisplatin, and the addition of bevacizumab to a taxane and carboplatin. Pemetrexed is used for maintenance therapy for non-squamous NSCLC, whereas patients with squamous NSCLC lack easy options for maintenance therapy. nab-Paclitaxel overcomes the solubility and toxicity issues of solvent-based paclitaxel, and the albumin in nab-paclitaxel improves the concentration of the drug in the tumor. A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P&lt;.001). Another subset analysis found that patients ages 70 years and older had improved overall survival (median 19.9 months) with nab-paclitaxel compared with solvent-based paclitaxel (median 10.4 months; P=.009). Patients in the nab-paclitaxel arm had less neuropathy, less hearing loss, and fewer interruptions in daily living than patients in the solvent-based paclitaxel arm.</AbstractText>
            </Abstract>
            <Affiliation>University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Socinski</LastName>
                    <ForeName>Mark A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Govindan</LastName>
                    <ForeName>Ramaswamy</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spigel</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Adv Hematol Oncol</MedlineTA>
            <NlmUniqueID>101167661</NlmUniqueID>
            <ISSNLinking>1543-0790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance>Receptor, Epidermal Growth Factor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Maintenance Chemotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Taxoids</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23187688</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23249848</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>12</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1024-2708</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18 Suppl 6</Volume>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine</Title>
                <ISOAbbreviation>Hong Kong Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term neurocognitive outcomes of children prenatally exposed to low-dose methylmercury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>23-4</MedlinePgn>
            </Pagination>
            <Affiliation>Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China. hshslam@cuhk.edu.hk</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lam</LastName>
                    <ForeName>H S H S</ForeName>
                    <Initials>HS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fok</LastName>
                    <ForeName>T F</ForeName>
                    <Initials>TF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>P C</ForeName>
                    <Initials>PC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Hong Kong Med J</MedlineTA>
            <NlmUniqueID>9512509</NlmUniqueID>
            <ISSNLinking>1024-2708</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Methylmercury Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7439-97-6</RegistryNumber>
                <NameOfSubstance>Mercury</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cognition</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fetal Blood</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fishes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Food Quality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mercury</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Methylmercury Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prenatal Exposure Delayed Effects</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23249848</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23063395</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2212-4411</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>114</Volume>
                    <Issue>5 Suppl</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oral surgery, oral medicine, oral pathology and oral radiology</Title>
                <ISOAbbreviation>Oral Surg Oral Med Oral Pathol Oral Radiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>1,25Dihydroxy vitamin D(3) improves titanium implant osseointegration in osteoporotic rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S174-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oooo.2011.09.030</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S2212-4403(12)00106-X</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the effects of 1,25(OH)(2)D(3) on implant osseointegration in osteoporotic rats.</AbstractText>
                <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Twelve weeks after bilateral ovariectomy, each rat had 2 titanium screws implanted in the proximal tibiae. All animals were then randomly divided into 2 groups: control (10 rats) and 1,25(OH)(2)D(3) (10 rats). 1,25(OH)(2)D(3) was administered through oral gavage at 0.1 μg/kg/d, and control animals were given vehicle. Eight weeks later, tibiae with screws were harvested for μCT, histologic, and biomechanical analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with control, 1,25(OH)(2)D(3) increased percent bone volume by 96.0%, percent osseointegration by 94.4%, mean trabecular number by 112.5%, mean trabecular thickness by 51.8%, trabecular connective density by 38.0%, and decreased trabecular separation by 39.3% in μCT analysis. The 1,25(OH)(2)D(3) increased bone area density by 1.2-fold and bone-to-implant contact by 1.5-fold in histomorphometry, and increased the maximal push-out force by 2.0-fold in biomechanical test.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The 1,25(OH)(2)D(3) improves implant osseointegration in osteoporotic rats.</AbstractText>
                <CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <Affiliation>Faculty, State Key Laboratory of Oral Diseases and Center of Orthognathic Surgery, Sichuan University, West China College of Stomatology, Chengdu, China.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Chenchen</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yunfeng</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xuemei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shui</LastName>
                    <ForeName>Xueping</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>05</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oral Surg Oral Med Oral Pathol Oral Radiol</MedlineTA>
            <NlmUniqueID>101576782</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>67-97-0</RegistryNumber>
                <NameOfSubstance>Cholecalciferol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7440-32-6</RegistryNumber>
                <NameOfSubstance>Titanium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>D</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bone Density</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cholecalciferol</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dental Implantation, Endosseous</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Histological Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Implants, Experimental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Osseointegration</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Osteoporosis</DescriptorName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ovariectomy</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tibia</DescriptorName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Titanium</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">X-Ray Microtomography</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S2212-4403(12)00106-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.oooo.2011.09.030</ArticleId>
            <ArticleId IdType="pubmed">23063395</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23063390</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2212-4411</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>114</Volume>
                    <Issue>5 Suppl</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oral surgery, oral medicine, oral pathology and oral radiology</Title>
                <ISOAbbreviation>Oral Surg Oral Med Oral Pathol Oral Radiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Distracted mandible does not reach the same strength as normal mandible in rabbits.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S140-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oooo.2011.09.024</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S2212-4403(12)00081-8</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to determine the resistance and fracture strength values of the bone with the use of biomechanical tests in different consolidation periods of mandibular distraction osteogenesis.</AbstractText>
                <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">In this study, 21 mature male New Zeland rabbits were used. After distraction, rabbits were separated into 3 groups to experience 4, 8, and 12 weeks' consolidation periods. Nonoperated hemimandibles of 6 rabbits were used as a control group. After 5 days' latency period, 0.5-mm distraction was applied twice a day, i.e., 1 mm/d lengthening. After the 5-mm lengthening application, we left the animals for 1, 2, or 3 months of consolidation period. Bending stress and strength values of the bone at fracture point were measured with the use of a 3-point bending test.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant differences between the control and 3 study groups regarding bending stress and strength values. In addition, each study group was significantly different from each other.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bending stress and fracture strength of the bone may not reach that of normal bone after completion of 3 months' consolidation. It should be considered to keep in place extraoral appliances or comfortable intraoral distractors for a long period.</AbstractText>
                <CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <Affiliation>Resident, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Selcuk University, Konya, Turkey.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bulut</LastName>
                    <ForeName>Türker</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Durmuş</LastName>
                    <ForeName>Ercan</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mihmanlı</LastName>
                    <ForeName>Ahmet</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dolanmaz</LastName>
                    <ForeName>Doğan</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalaycı</LastName>
                    <ForeName>Abdullah</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sağlam</LastName>
                    <ForeName>Hacı</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>04</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oral Surg Oral Med Oral Pathol Oral Radiol</MedlineTA>
            <NlmUniqueID>101576782</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>D</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bone Regeneration</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dental Stress Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mandible</DescriptorName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Osteogenesis, Distraction</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rabbits</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2011</Year>
                <Month>8</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S2212-4403(12)00081-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.oooo.2011.09.024</ArticleId>
            <ArticleId IdType="pubmed">23063390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23536531</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-6817</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>148</Volume>
                    <Issue>4 Suppl</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery</Title>
                <ISOAbbreviation>Otolaryngol Head Neck Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Panel 3: Recent advances in anatomy, pathology, and cell biology in relation to otitis media pathogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E37-51</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0194599813476257</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">The pathogenesis of otitis media (OM) involves a number of factors related to the anatomy, pathology, and cell biology of the middle ear, the mastoid, the Eustachian tube, and the nasopharynx. Although some issues of pathogenesis are fairly well established, others are only marginally indicated by current knowledge, and yet others remain undisclosed. The objective of this article is to provide a state-of-the-art review on recent scientific achievements in the pathogenesis of OM, as related to anatomy, pathology, and cell biology.</AbstractText>
                <AbstractText Label="DATA SOURCES" NlmCategory="METHODS">PubMed, Ovid Medline, and Cochrane Library.</AbstractText>
                <AbstractText Label="REVIEW METHODS" NlmCategory="METHODS">Articles published on the pathogenesis of OM and the anatomy, pathology, and cell biology of the middle ear, the mastoid, the Eustachian tube, and the nasopharynx between January 2007 and June 2011 were identified. Among almost 1900 abstracts, the authors selected 130 articles for full article review and inclusion in this report.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">New knowledge on a number of issues emerged, including cell-specific expression and function of fluid transportation and innate immune system molecules, mucous cell metaplasia, mucin expression, bacterial adherence, and epithelial internalization, as well as the occurrence, composition, dynamics, and potential role of bacterial biofilm. In addition, the potential role of gastroesophageal reflux disease and cigarette smoke exposure has been explored further.</AbstractText>
                <AbstractText Label="CONCLUSIONS AND IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">Over the past 4 years, considerable scientific progress has been made on the pathogenesis of OM, as related to issues of anatomy, pathology, and cell biology. Based on these new achievements and a sustained lack of essential knowledge, suggestions for future research are outlined.</AbstractText>
            </Abstract>
            <Affiliation>Department of Oto-rhino-laryngology, Head and Neck Surgery, University Hospital of Copenhagen, Copenhagen, Denmark. per.caye.thomasen@regionh.dk</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cayé-Thomasen</LastName>
                    <ForeName>Per</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hermansson</LastName>
                    <ForeName>Ann</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bakaletz</LastName>
                    <ForeName>Lauren</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hellstrøm</LastName>
                    <ForeName>Sten</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanzaki</LastName>
                    <ForeName>Sho</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kerschner</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Jizhen</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mason</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spratley</LastName>
                    <ForeName>Jorge</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Otolaryngol Head Neck Surg</MedlineTA>
            <NlmUniqueID>8508176</NlmUniqueID>
            <ISSNLinking>0194-5998</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Ear, Middle</DescriptorName>
                <QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eustachian Tube</DescriptorName>
                <QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gastroesophageal Reflux</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Mastoid</DescriptorName>
                <QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Nasopharynx</DescriptorName>
                <QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Otitis Media</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">148/4_suppl/E37</ArticleId>
            <ArticleId IdType="doi">10.1177/0194599813476257</ArticleId>
            <ArticleId IdType="pubmed">23536531</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23536025</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1476-5543</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of perinatology : official journal of the California Perinatal Association</Title>
                <ISOAbbreviation>J Perinatol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Health consequences of shift work and implications for structural design.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S17-23</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/jp.2013.7</ELocationID>
            <Abstract>
                <AbstractText>The objective of the study was to perform a literature review on the health consequences of working rotating shifts and implications for structural design. A literature search was performed in June 2012 and a selection of the most relevant peer-review articles was included in the present review. Shift workers are more likely to suffer from a circadian sleep disorder characterized by sleepiness and insomnia. Shift work is associated with decreased productivity, impaired safety, diminished quality of life and adverse effects on health. Circadian disruption resulting from rotating shift work has also been associated with increased risk for metabolic syndrome, diabetes, cardiovascular disease and cancer. This article summarizes the known health effects of shift work and discusses how light can be used as a countermeasure to minimize circadian disruption at night while maintaining alertness. In the context of the lighted environment, implications for the design of newborn intensive care units are also discussed.</AbstractText>
            </Abstract>
            <Affiliation>Lighting Research Center, Rensselaer Polytechnic Institute, Troy, NY 12180, USA. figuem@rpi.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Figueiro</LastName>
                    <ForeName>M G</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>White</LastName>
                    <ForeName>R D</ForeName>
                    <Initials>RD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Perinatol</MedlineTA>
            <NlmUniqueID>8501884</NlmUniqueID>
            <ISSNLinking>0743-8346</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>73-31-4</RegistryNumber>
                <NameOfSubstance>Melatonin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Circadian Rhythm</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Hospital Design and Construction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intensive Care Units, Neonatal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lighting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Melatonin</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Occupational Health</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quality of Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sleep Disorders, Circadian Rhythm</DescriptorName>
                <QualifierName MajorTopicYN="Y">complications</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jp20137</ArticleId>
            <ArticleId IdType="doi">10.1038/jp.2013.7</ArticleId>
            <ArticleId IdType="pubmed">23536025</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23535053</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1879-1972</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>4 Suppl</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of adolescent health : official publication of the Society for Adolescent Medicine</Title>
                <ISOAbbreviation>J Adolesc Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intrauterine devices and pelvic inflammatory disease among adolescents.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S22-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jadohealth.2013.01.017</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1054-139X(13)00059-1</ELocationID>
            <Abstract>
                <AbstractText>Adolescents may be ideal candidates for intrauterine device (IUD) use, given high rates of unintended pregnancy and less successful use of short-acting contraceptive methods. Concerns about elevated risks of pelvic inflammatory disease in adolescents, with the consequences of infertility, ectopic pregnancy, and pelvic pain, prevent many clinicians from inserting IUDs in adolescents. The body of evidence examining risks of pelvic infection related to IUD use specifically in adolescents is limited, but is reassuring that the absolute risk of pelvic infection is small and that the benefits of IUD use likely outweigh the risks.</AbstractText>
                <CopyrightInformation>Copyright © 2013 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <Affiliation>Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Carr</LastName>
                    <ForeName>Shannon</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Espey</LastName>
                    <ForeName>Eve</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Adolesc Health</MedlineTA>
            <NlmUniqueID>9102136</NlmUniqueID>
            <ISSNLinking>1054-139X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intrauterine Devices</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pelvic Inflammatory Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy in Adolescence</DescriptorName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1054-139X(13)00059-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jadohealth.2013.01.017</ArticleId>
            <ArticleId IdType="pubmed">23535053</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23535052</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1879-1972</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>4 Suppl</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of adolescent health : official publication of the Society for Adolescent Medicine</Title>
                <ISOAbbreviation>J Adolesc Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Myths and misconceptions about long-acting reversible contraception (LARC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>S14-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jadohealth.2013.02.003</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1054-139X(13)00063-3</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To discuss common myths and misconceptions about long-acting reversible contraception (LARC) among patients and health care providers.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We address some of these common myths in an effort to provide clinicians with accurate information to discuss options with patients, parents, and referring providers. The list of myths was created through an informal survey of an online listserv of 200 family planning experts and from the experiences of the authors.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">When presented with information about LARC, adolescents are more likely to request LARC and are satisfied with LARC. Clinicians have an important role in counseling about and providing LARC to their adolescent patients as well as supporting them in managing associated side effects.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This review article can be used as a resource for contraceptive counseling visits and for the continuing education of health professionals providing adolescent reproductive health care.</AbstractText>
                <CopyrightInformation>Copyright © 2013 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <Affiliation>Planned Parenthood of Orange and San Bernardino Counties, Orange, California 92866, USA. jennefer.russo@pposbc.org</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Russo</LastName>
                    <ForeName>Jennefer A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gold</LastName>
                    <ForeName>Melanie A</ForeName>
                    <Initials>MA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Adolesc Health</MedlineTA>
            <NlmUniqueID>9102136</NlmUniqueID>
            <ISSNLinking>1054-139X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Consumer Health Information</DescriptorName>
                <QualifierName MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intrauterine Devices</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy in Adolescence</DescriptorName>
                <QualifierName MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Truth Disclosure</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1054-139X(13)00063-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jadohealth.2013.02.003</ArticleId>
            <ArticleId IdType="pubmed">23535052</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23532441</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1468-2060</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>72 Suppl 2</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of the rheumatic diseases</Title>
                <ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.</ArticleTitle>
            <Pagination>
                <MedlinePgn>ii2-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2013-203348</ELocationID>
            <Affiliation>Department of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA. defurst@mednet.ucla.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Furst</LastName>
                    <ForeName>Daniel E</ForeName>
                    <Initials>DE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keystone</LastName>
                    <ForeName>Edward Clark</ForeName>
                    <Initials>EC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>So</LastName>
                    <ForeName>Alexander K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braun</LastName>
                    <ForeName>Jürgen</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breedveld</LastName>
                    <ForeName>Ferry C</ForeName>
                    <Initials>FC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burmester</LastName>
                    <ForeName>Gerd R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Benedetti</LastName>
                    <ForeName>Fabrizio</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dörner</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Emery</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleischmann</LastName>
                    <ForeName>Roy</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gibofsky</LastName>
                    <ForeName>Allan</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalden</LastName>
                    <ForeName>J R</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kavanaugh</LastName>
                    <ForeName>Arthur</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirkham</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mease</LastName>
                    <ForeName>Philip</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubbert-Roth</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sieper</LastName>
                    <ForeName>Joachim</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singer</LastName>
                    <ForeName>Nora G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smolen</LastName>
                    <ForeName>Josef S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Riel</LastName>
                    <ForeName>Piet L C M</ForeName>
                    <Initials>PL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weisman</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winthrop</LastName>
                    <ForeName>Kevin L</ForeName>
                    <Initials>KL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Consensus Development Conference</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Rheum Dis</MedlineTA>
            <NlmUniqueID>0372355</NlmUniqueID>
            <ISSNLinking>0003-4967</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antirheumatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunoconjugates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Pegloticase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Polyethylene Glycols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>tocilizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73B0K5S26A</RegistryNumber>
                <NameOfSubstance>belimumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7D0YB67S97</RegistryNumber>
                <NameOfSubstance>abatacept</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.7.3.3</RegistryNumber>
                <NameOfSubstance>Urate Oxidase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoconjugates</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rheumatic Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Urate Oxidase</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">annrheumdis-2013-203348</ArticleId>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-203348</ArticleId>
            <ArticleId IdType="pubmed">23532441</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23529570</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-4413</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>138 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].</ArticleTitle>
            <Pagination>
                <MedlinePgn>S6-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1305283</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy.</AbstractText>
                <AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">This 52-week, double-blind, multicenter, active-controlled, noninferiority trial randomized patients with type 2 diabetes (baseline mean HbA1c, 7.7 %), who were receiving metformin monotherapy, to add-on dapagliflozin (n = 406) or glipizide (n = 408) up-titrated over 18 weeks, based on glycemic response and tolerability, to ≤ 10 or ≤ 20 mg/day, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary end point, adjusted mean HbA1c reduction with dapagliflozin (-0.52 %) compared with glipizide (-0.52 %), was statistically noninferior at 52 weeks. Key secondary end points: dapagliflozin produced significant adjusted mean weight loss (-3.2 kg) versus weight gain (1.2 kg; P &lt; 0.0001) with glipizide, significantly increased the proportion of patients achieving ≥ 5 % body weight reduction (33.3 %) versus glipizide (2.5 %; p &lt; 0.0001), and significantly decreased the proportion experiencing hypoglycemia (3.5 %) versus glipizide (40.8 %; p &lt; 0.0001). Events suggestive of genital infections and lower urinary tract infections were reported more frequently with dapagliflozin compared with glipizide but responded to standard treatment and rarely led to study discontinuation.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin. Long-term studies are required to further evaluate genital and urinary tract infections with SGLT2 inhibitors.</AbstractText>
                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
            </Abstract>
            <Affiliation>Diabeteszentrum, Bad Lauterberg, Deutschland. m.nauck@diabeteszentrum.de</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nauck</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>del Prato</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meier</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Durán-García</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rohwedder</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elze</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parikh</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00660907</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType>Clinical Trial, Phase III</PublicationType>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Multicenter Study</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Vergleich von Dapagliflozin und Glipizid als Add-on-Therapie bei Typ-2-Diabetikern mit unzureichender Blutzuckerkontrolle unter Metformin.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucosides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hemoglobin A, Glycosylated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>SLC5A2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sodium-Glucose Transporter 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>hemoglobin A1c protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>29094-61-9</RegistryNumber>
                <NameOfSubstance>Glipizide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>657-24-9</RegistryNumber>
                <NameOfSubstance>Metformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Balanitis</DescriptorName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Candidiasis, Vulvovaginal</DescriptorName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glipizide</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucosides</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Urinary Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1305283</ArticleId>
            <ArticleId IdType="pubmed">23529570</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23529569</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-4413</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>138 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].</ArticleTitle>
            <Pagination>
                <MedlinePgn>S4-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1305325</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nauck</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Del Prato</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Editorial</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>SGLT-2-Inhibitor Dapagliflozin: Neuer Therapieansatz für den Typ-2-Diabetes, neue Erfolge, aber auch neue Fragen!</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucosides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hemoglobin A, Glycosylated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>SLC5A2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sodium-Glucose Transporter 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sulfonylurea Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>hemoglobin A1c protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>29094-61-9</RegistryNumber>
                <NameOfSubstance>Glipizide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>657-24-9</RegistryNumber>
                <NameOfSubstance>Metformin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>93479-97-1</RegistryNumber>
                <NameOfSubstance>glimepiride</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glipizide</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucosides</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glycosuria</DescriptorName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1305325</ArticleId>
            <ArticleId IdType="pubmed">23529569</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23529568</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-4413</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>138 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].</ArticleTitle>
            <Pagination>
                <MedlinePgn>S27-38</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1305284</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of adding dapagliflozin therapy in patients whose type 2 diabetes mellitus is inadequately controlled with insulin with or without oral antidiabetic drugs.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">A 24-week, randomized, placebo-controlled, multicenter trial followed by a 24-week extension period. An additional 56-week extension period is ongoing. (ClinicalTrials.gov registration number: NCT00673231). SettinG: 126 centers in Europe and North America from 30 April 2008 to 19 November 2009.</AbstractText>
                <AbstractText Label="PATIENTS" NlmCategory="METHODS">808 patients with inadequately controlled type 2 diabetes mellitus receiving at least 30 U of insulin daily, with or without up to 2 oral antidiabetic drugs.</AbstractText>
                <AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were randomly assigned in a 1:1:1:1 ratio and allocated with a computer-generated scheme to receive placebo or 2.5, 5, or 10 mg of dapagliflozin, once daily, for 48 weeks.</AbstractText>
                <AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">The primary outcome was change in hemoglobin A1c from baseline to 24 weeks. Secondary outcomes included changes in body weight, insulin dose, and fasting plasma glucose level at 24 weeks and during the 24-week extension period. Adverse events were evaluated throughout both 24-week periods.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">800 patients were analyzed. After 24 weeks, mean hemoglobin A1c decreased by 0.79 % to 0.96 % with dapagliflozin compared with 0.39 % with placebo (mean difference, -0.40 % [95 % CI, -0.54 % to -0.25 %] in the 2.5-mg group, -0.49 % [CI, -0.65 % to -0.34 %] in the 5-mg group, and -0.57 % [CI, -0.72 % to -0.42 %] in the 10-mg group). Daily insulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean difference, -7.60 U [CI, -10.32 to -4.87 U] in the 2.5-mg group, -6.28 U [CI, -8.99 to -3.58 U] in the 5-mg group, and -6.82 U [CI, -9.56 to -4.09 U] in the 10-mg group). Body weight decreased by 0.92 to 1.61 kg with dapagliflozin and increased by 0.43 kg with placebo (mean differences, -1.35 kg [CI, -1.90 to -0.80 kg] in the 2.5-mg group, -1.42 kg [CI, -1.97 to -0.88 kg] in the 5-mg group, and -2.04 kg [CI, -2.59 to -1.48 kg] in the 10-mg group). These effects were maintained at 48 weeks. Compared with the placebo group, patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes (56.6 % vs. 51.8 %), events suggesting genital infection (9.0 % vs. 2.5 %), and events suggesting urinary tract infection (9.7 % vs. 5.1 %).</AbstractText>
                <AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">Insulin doses were not titrated to target, and the study was not designed to evaluate long-term safety.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major hypoglycemic episodes in patients with inadequately controlled type 2 diabetes mellitus.</AbstractText>
                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
            </Abstract>
            <Affiliation>Forschungsgruppe Diabetes und Endokrinologie, Abteilung Adipositas und Endokrinologie, Zentrum für klinische Wissenschaft, Universitätsklinik Aintree, Liverpool, UK. j.p.h.wilding@liverpool.ac.uk</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wilding</LastName>
                    <ForeName>J P H</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woo</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soler</LastName>
                    <ForeName>N G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pahor</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugg</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rohwedder</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parikh</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Studiengruppe Dapagliflozin 006</CollectiveName>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00673231</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Multicenter Study</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Langzeitwirkung von Dapagliflozin bei Typ-2-Diabetikern unter hoch dosierter Insulintherapie.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucosides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hemoglobin A, Glycosylated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>SLC5A2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sodium-Glucose Transporter 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>hemoglobin A1c protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>657-24-9</RegistryNumber>
                <NameOfSubstance>Metformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucosides</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Long-Term Care</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1305284</ArticleId>
            <ArticleId IdType="pubmed">23529568</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23529567</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-4413</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>138 Suppl 1</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].</ArticleTitle>
            <Pagination>
                <MedlinePgn>S16-26</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1305277</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Progressive deterioration of glycaemic control in type 2 diabetes mellitus (T2DM) often requires treatment intensification. Dapagliflozin increases urinary glucose excretion by selective inhibition of renal sodium-glucose cotransporter 2 (SGLT2). We assessed the efficacy, safety and tolerability of dapagliflozin added to glimepiride in patients with uncontrolled T2DM.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This 24-week, randomized, double-blind, placebo-controlled, parallel-group, international, multicentre trial (ClinicalTrials.gov NCT00680745) enrolled patients with uncontrolled T2DM [haemoglobin A1c (HbA1c) 7-10 %] receiving sulphonylurea monotherapy. Adult patients (n = 597) were randomly assigned to placebo or dapagliflozin (2.5, 5 or 10 mg/day) added to open-label glimepiride 4 mg/day for 24 weeks. Primary endpoint was HbA1c mean change from baseline at 24 weeks. Secondary endpoints included change in body weight and other glycaemic parameters.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">At 24 weeks, HbA1c adjusted mean changes from baseline for placebo versus dapagliflozin 2.5/5/10 mg groups were -0.13 versus -0.58, -0.63, -0.82 %, respectively (all p &lt; 0.0001 vs. placebo by Dunnett's procedure). Corresponding body weight and fasting plasma glucose values were -0.72, -1.18, -1.56, -2.26 kg and -0.11, -0.93, -1.18, -1.58 mmol/l, respectively. In placebo versus dapagliflozin groups, serious adverse events were 4.8 versus 6.0-7.1 %; hypoglycaemic events 4.8 versus 7.1-7.9 %; events suggestive of genital infection 0.7 versus 3.9-6.6 %; and events suggestive of urinary tract infection 6.2 versus 3.9-6.9 %. No kidney infections were reported.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dapagliflozin added to glimepiride in patients with T2DM uncontrolled on sulphonylurea monotherapy significantly improved HbA1c, reduced weight and was generally well tolerated, although events suggestive of genital infections were reported more often in patients receiving dapagliflozin.</AbstractText>
                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
            </Abstract>
            <Affiliation>Department of Internal Diseases, Diabetology and Nephrology, Silesian Medical University, Zabrze, Polen. KSTROJEK@sum.edu.pl</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Strojek</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoon</LastName>
                    <ForeName>K H</ForeName>
                    <Initials>KH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hruba</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elze</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langkilde</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parikh</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00680745</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType>Clinical Trial, Phase III</PublicationType>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Multicenter Study</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Effekt von Dapagliflozin bei Typ-2-Diabetikern mit unzureichender Blutzuckereinstellung unter Glimepirid.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucosides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hemoglobin A, Glycosylated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>SLC5A2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sodium-Glucose Transporter 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sulfonylurea Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>hemoglobin A1c protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>93479-97-1</RegistryNumber>
                <NameOfSubstance>glimepiride</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Body Mass Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucosides</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1305277</ArticleId>
            <ArticleId IdType="pubmed">23529567</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526541</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Delayed perforation 10 days after endoscopic hemostasis using hemostatic forceps for a bleeding Dieulafoy lesion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E99-100</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326275</ELocationID>
            <Affiliation>Department of Surgery, Arita Gastrointestinal Hospital, Oita, Japan. sninomiy@med.oita-u.ac.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ninomiya</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiroshita</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bandoh</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soma</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abe</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arita</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arteriovenous Malformations</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemostasis, Endoscopic</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stomach</DescriptorName>
                <QualifierName MajorTopicYN="N">blood supply</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stomach Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326275</ArticleId>
            <ArticleId IdType="pubmed">23526541</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526540</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Life-threatening angiocholitis following clot formation after balloon dilation for extraction of a large stone in the lower bile duct.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E97-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326248</ELocationID>
            <Affiliation>Centre Clinical-Gastro BBMM, Soyaux, France. bmaroy@yahoo.fr</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maroy</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cholangiopancreatography, Endoscopic Retrograde</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cholangitis</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cholelithiasis</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dilatation</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sepsis</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sphincterotomy, Endoscopic</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326248</ArticleId>
            <ArticleId IdType="pubmed">23526540</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526538</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cerebral air embolism: a rare complication following balloon dilation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E93-4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326251</ELocationID>
            <Affiliation>Department of Gastroenterology, Queen Elizabeth Hospital Woolwich, United Kingdom.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pee</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basu</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loganayagam</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Deglutition Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dilatation</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Embolism, Air</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Stenosis</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intracranial Embolism</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326251</ArticleId>
            <ArticleId IdType="pubmed">23526538</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526537</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Delayed perforation after intralesional triamcinolone injection for esophageal stricture following endoscopic submucosal dissection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E92</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326253</ELocationID>
            <Affiliation>Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yamashina</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uedo</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujii</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ishihara</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mikamori</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Motoori</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yano</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iishi</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>124-94-7</RegistryNumber>
                <NameOfSubstance>Triamcinolone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carcinoma</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dilatation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dissection</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Perforation</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Stenosis</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Injections, Intralesional</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mucous Membrane</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Triamcinolone</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326253</ArticleId>
            <ArticleId IdType="pubmed">23526537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526536</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fatal massive air embolism following diagnostic colonoscopy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E91</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326254</ELocationID>
            <Affiliation>Digestive Diseases Department, Corporació Sanitaria Parc Tauli, Sabadell, Spain. gulab2132@yahoo.es</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sopeña-Falco</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poch-Vall</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brullet</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mendez-Reyes</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez-Bauer</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Junquera</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pujol-Caballe</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campo</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Colonoscopy</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Embolism, Air</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326254</ArticleId>
            <ArticleId IdType="pubmed">23526536</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526535</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Spontaneous intraductal stent migration after endoscopic ultrasound-guided choledochogastrostomy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E89-90</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326255</ELocationID>
            <Affiliation>Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kawakubo</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawakami</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuwatani</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haba</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kudo</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abe</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakamoto</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Video-Audio Media</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cholangitis</DescriptorName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Choledochostomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drainage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gastrostomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stents</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ultrasonography, Interventional</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326255</ArticleId>
            <ArticleId IdType="pubmed">23526535</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526534</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endoscopic closure of transmural esophageal perforation after balloon dilation for achalasia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E88</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326257</ELocationID>
            <Affiliation>Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands. sjb.vanweyenberg@vumc.nl</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Van Weyenberg</LastName>
                    <ForeName>S J B</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Boer</LastName>
                    <ForeName>N K</ForeName>
                    <Initials>NK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zonderhuis</LastName>
                    <ForeName>B M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Peet</LastName>
                    <ForeName>D L</ForeName>
                    <Initials>DL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dilatation</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Achalasia</DescriptorName>
                <QualifierName MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Esophageal Perforation</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Esophagoscopy</DescriptorName>
                <QualifierName MajorTopicYN="N">instrumentation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326257</ArticleId>
            <ArticleId IdType="pubmed">23526534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526529</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gastric balloon causing small bowel obstruction: treatment by double-balloon enteroscopy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E78-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326265</ELocationID>
            <Affiliation>Park-Krankenhaus Leipzig, Klinik für Innere Medizin II, Leipzig, Germany. ulrich.halm@parkkrankenhaus-leipzig.de</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Halm</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grothoff</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lamberts</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Balloon Enteroscopy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gastric Balloon</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intestinal Obstruction</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Jejunal Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326265</ArticleId>
            <ArticleId IdType="pubmed">23526529</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526528</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Choledochoduodenal fistula after biliary placement of a self-expanding metallic stent for palliation of pancreatic cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E77</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326266</ELocationID>
            <Affiliation>Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA. Chaudharidhara@yahoo.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chaudhari</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saleem</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murthy</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baron</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biliary Fistula</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Common Bile Duct Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Duodenal Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Exsanguination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intestinal Fistula</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Palliative Care</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Stents</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326266</ArticleId>
            <ArticleId IdType="pubmed">23526528</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23526527</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1438-8812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45 Suppl 2 UCTN</Volume>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Endoscopy</Title>
                <ISOAbbreviation>Endoscopy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Application of endoscopic double illumination technique for management of anastomotic site membranes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>E75-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1326243</ELocationID>
            <Affiliation>Department of Internal Medicine, Wyckoff Heights Medical Center, Brooklyn, New York 11237, USA. giresearch2011@hotmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rafiq</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nemat</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgan</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabbagh</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Endoscopy</MedlineTA>
            <NlmUniqueID>0215166</NlmUniqueID>
            <ISSNLinking>0013-726X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anastomosis, Surgical</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Colectomy</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Colon</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Colonoscopy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ileostomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intestinal Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rectum</DescriptorName>
                <QualifierName MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Transillumination</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1326243</ArticleId>
            <ArticleId IdType="pubmed">23526527</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
